%PDF-1.5
%
1 0 obj
<<
/Lang (en)
/MarkInfo <<
/Marked true
>>
/Metadata 2 0 R
/Outlines 3 0 R
/PageLayout /OneColumn
/PageMode /UseOutlines
/Pages 4 0 R
/StructTreeRoot 5 0 R
/Type /Catalog
/ViewerPreferences <<
/DisplayDocTitle true
>>
>>
endobj
6 0 obj
<<
/Author (Gemeinsamer Bundesausschuss/Federal Joint Committee)
/Category ()
/Comments ()
/Company ()
/CreationDate (D:20210929142229+02'00')
/Creator <4163726F626174205044464D616B65722031352066FC7220576F7264>
/Keywords <416E6E65782058494920852042656E65666974204173736573736D656E74206F66204D65646963696E616C2050726F64756374732077697468204E65772041637469766520496E6772656469656E7473206163636F7264696E6720746F2053656374696F6E203335612053474220560D0A53656C706572636174696E69622028746879726F69642063616E6365722C2052455420667573696F6E2D706F7369746976652C206166746572207072696F722074686572617079207769746820736F726166656E696220616E642F6F72206C656E766174696E6962290D0A>
/ModDate (D:20210929142430+02'00')
/Producer (Adobe PDF Library 15.0)
/SourceModified (D:20210928071747)
/Subject (Pharmaceuticals Directive \(AM-RL\):)
/Title (Resolution)
>>
endobj
2 0 obj
<<
/Length 4772
/Subtype /XML
/Type /Metadata
>>
stream
2021-09-29T14:24:30+02:00
2021-09-29T14:22:29+02:00
2021-09-29T14:24:30+02:00
Acrobat PDFMaker 15 für Word
uuid:2470bc2c-8752-4c01-abe1-d87ded385fc4
uuid:17e0730a-e6e9-495b-a5c5-71fcf0e770d3
1
application/pdf
Resolution
Pharmaceuticals Directive (AM-RL):
Gemeinsamer Bundesausschuss/Federal Joint Committee
(g-ba.de)
Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V
Selpercatinib (thyroid cancer
RET fusion-positive
after prior therapy with sorafenib and/or lenvatinib)
Adobe PDF Library 15.0
Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V
Selpercatinib (thyroid cancer, RET fusion-positive, after prior therapy with sorafenib and/or lenvatinib)
D:20210928071747
endstream
endobj
3 0 obj
<<
/Count 9
/First 7 0 R
/Last 8 0 R
/Type /Outlines
>>
endobj
4 0 obj
<<
/Count 4
/Kids [9 0 R 10 0 R 11 0 R 12 0 R]
/Type /Pages
>>
endobj
5 0 obj
<<
/K 13 0 R
/ParentTree 14 0 R
/ParentTreeNextKey 9
/RoleMap 15 0 R
/Type /StructTreeRoot
>>
endobj
7 0 obj
<<
/A 16 0 R
/Count 3
/First 17 0 R
/Last 18 0 R
/Next 8 0 R
/Parent 3 0 R
/Title (SSResolution)
>>
endobj
8 0 obj
<<
/A 19 0 R
/Count 4
/First 20 0 R
/Last 21 0 R
/Parent 3 0 R
/Prev 7 0 R
/Title (I. In Annex XII, the following information shall be added after No. 4 to the information on the benefit assessment of selpercatinib in accordance with the resolution of 2 September 2021:)
>>
endobj
9 0 obj
<<
/Contents [22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/ColorSpace <<
/CS0 [/ICCBased 31 0 R]
/CS1 [/ICCBased 32 0 R]
>>
/Font <<
/TT0 33 0 R
/TT1 34 0 R
/TT2 35 0 R
>>
/XObject <<
/OL1 36 0 R
>>
>>
/Rotate 0
/StructParents 0
/Tabs /S
/Type /Page
>>
endobj
10 0 obj
<<
/Contents [37 0 R 38 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/ColorSpace <<
/CS0 [/ICCBased 31 0 R]
>>
/Font <<
/TT0 33 0 R
/TT1 34 0 R
/TT2 35 0 R
/TT3 39 0 R
>>
/XObject <<
/OL1 36 0 R
>>
>>
/Rotate 0
/StructParents 1
/Tabs /S
/Type /Page
>>
endobj
11 0 obj
<<
/Annots [40 0 R 41 0 R 42 0 R]
/Contents [43 0 R 44 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/ColorSpace <<
/CS0 [/ICCBased 31 0 R]
/CS1 [/ICCBased 32 0 R]
>>
/Font <<
/C2_0 45 0 R
/C2_1 46 0 R
/TT0 33 0 R
/TT1 34 0 R
/TT2 35 0 R
>>
/XObject <<
/OL1 36 0 R
>>
>>
/Rotate 0
/StructParents 2
/Tabs /S
/Type /Page
>>
endobj
12 0 obj
<<
/Annots [47 0 R 48 0 R]
/Contents [49 0 R 50 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/ColorSpace <<
/CS0 [/ICCBased 31 0 R]
/CS1 [/ICCBased 32 0 R]
>>
/Font <<
/TT0 33 0 R
/TT1 51 0 R
/TT2 34 0 R
/TT3 35 0 R
>>
/XObject <<
/OL1 36 0 R
>>
>>
/Rotate 0
/StructParents 5
/Tabs /S
/Type /Page
>>
endobj
13 0 obj
<<
/K [52 0 R 53 0 R 54 0 R 55 0 R 56 0 R 57 0 R 58 0 R 59 0 R 60 0 R 61 0 R
62 0 R 63 0 R 64 0 R 65 0 R 66 0 R 67 0 R 68 0 R 69 0 R 70 0 R 71 0 R
72 0 R 73 0 R 74 0 R 75 0 R 76 0 R 77 0 R 78 0 R 79 0 R 80 0 R 81 0 R
82 0 R 83 0 R 84 0 R 85 0 R 86 0 R 87 0 R 88 0 R 89 0 R 90 0 R 91 0 R
92 0 R 93 0 R 94 0 R 95 0 R 96 0 R 97 0 R 98 0 R 99 0 R 100 0 R 101 0 R
102 0 R 103 0 R 104 0 R 105 0 R 106 0 R 107 0 R 108 0 R 109 0 R]
/P 5 0 R
/S /Sect
>>
endobj
14 0 obj
<<
/Nums [0 [null 53 0 R 54 0 R 55 0 R 56 0 R 57 0 R 58 0 R 59 0 R 60 0 R 61 0 R
52 0 R]
1 [62 0 R 63 0 R 64 0 R 65 0 R 66 0 R 67 0 R 68 0 R 69 0 R 70 0 R 71 0 R
72 0 R 73 0 R 74 0 R null 76 0 R 77 0 R null null 110 0 R null
null null 111 0 R null null null 112 0 R null null 79 0 R
80 0 R 81 0 R 82 0 R 113 0 R]
2 [83 0 R 85 0 R 86 0 R null 114 0 R null 115 0 R null null 116 0 R
null 117 0 R null 118 0 R null null 119 0 R null 120 0 R null
121 0 R null 122 0 R null 123 0 R 124 0 R 125 0 R null 126 0 R null
127 0 R 128 0 R 129 0 R null 130 0 R null 131 0 R 132 0 R 133 0 R null
134 0 R null 135 0 R 136 0 R 137 0 R null 138 0 R null 139 0 R null
140 0 R null 141 0 R null 142 0 R null 143 0 R null 144 0 R null
145 0 R null 146 0 R 88 0 R 89 0 R 90 0 R 91 0 R null null null
93 0 R 94 0 R null 147 0 R null 148 0 R 83 0 R 149 0 R 150 0 R]
3 151 0 R 4 151 0 R
5 [95 0 R 96 0 R 97 0 R 98 0 R null 152 0 R null 153 0 R null null
154 0 R null 155 0 R null 156 0 R null 157 0 R null 158 0 R null
159 0 R null 160 0 R null 161 0 R 162 0 R null 163 0 R null 164 0 R
165 0 R null 166 0 R null 167 0 R null 168 0 R null 169 0 R null
170 0 R 171 0 R null 172 0 R null 173 0 R 174 0 R null 175 0 R null
176 0 R 177 0 R 100 0 R 101 0 R 102 0 R 103 0 R null null 178 0 R null
null 105 0 R null null 106 0 R 107 0 R 108 0 R 109 0 R 179 0 R 180 0 R]
6 181 0 R 7 181 0 R 8 148 0 R]
>>
endobj
15 0 obj
<<
/Annotation /Span
/Artifact /P
/Bibliography /BibEntry
/Chart /Figure
/Diagram /Figure
/DropCap /Figure
/Endnote /Note
/Footnote /Note
/GBA_Aufz#C3#A4hlung#201. /P
/GBA_Datum /P
/GBA_Standard /P
/GBA_Verfasser /P
/Hyperlink /Span
/InlineShape /Figure
/Outline /Span
/Standard /P
/Strikeout /Span
/Subscript /Span
/Superscript /Span
/TextBox /Art
/Titel /H1
/Underline /Span
/Untertitel /H2
/#C3#9Cberschrift#201 /H1
/#C3#9Cberschrift#204 /H4
>>
endobj
16 0 obj
<<
/D [9 0 R /XYZ 69 743 0.0]
/S /GoTo
>>
endobj
17 0 obj
<<
/A 182 0 R
/Next 183 0 R
/Parent 7 0 R
/Title (of the Federal Joint Committee \(G-BA\) on an Amendment of the Pharmaceuticals Directive \(AM-RL\):)
>>
endobj
18 0 obj
<<
/A 184 0 R
/Parent 7 0 R
/Prev 183 0 R
/Title (Selpercatinib \(thyroid cancer, RET fusion-positive, after prior therapy with sorafenib and/or lenvatinib\))
>>
endobj
19 0 obj
<<
/D [9 0 R /XYZ 69 444 0.0]
/S /GoTo
>>
endobj
20 0 obj
<<
/A 185 0 R
/Next 186 0 R
/Parent 8 0 R
/Title (1. Additional benefit of the medicinal product in relation to the appropriate comparator therapy)
>>
endobj
21 0 obj
<<
/A 187 0 R
/Parent 8 0 R
/Prev 188 0 R
/Title (4. Treatment costs)
>>
endobj
22 0 obj
<<
/Length 37
/Filter /FlateDecode
>>
stream
x+*23P0bdBr.KB W
endstream
endobj
23 0 obj
<<
/Length 797
/Filter /FlateDecode
>>
stream
HUMO1ﯘ?ƖCE zH >S}3^BTz;okϛ{v6Wtp0;Z.fwev||.rJ$
9Y2$կ>.旋Gۧ?PanU| Ӌs=Ӹf'g'bK%Q!4TȂyL[w!ARR5cKک7*>!VLf1bn] tɽXז1旅s!-Uj؆4,H5H"6hfrCݕic)a>i]ؖ呖@^ rc66an,EeYZ
I~,*
FaQꨢS=*dPF쩛
)Ra3կ "AH0b{
]ևrfcOΘe-gv~KNSՒ߱y
O
S=ЪAӬ!(_l/iMo`-N)ͣ1_)u n@WwK@N@LJe}j5־*95p٢
1{GHl\$ڕSr1?e@v,n+P־v}9oL_nXۈ=tvWwWmY8]j]ҕ9vLgګ,
ѵ"abNyϽ`;6X7d-NffW)B ҋ
endstream
endobj
24 0 obj
<<
/Length 873
/Filter /FlateDecode
>>
stream
HVInG+Mefg0ttC
#A"\"ݾ}s|X}>z8;v'>f!6mN\ %#lU Nz;mH